Navigation Links
Nausea Drug Shows Promise Against Opioid Addiction
Date:2/18/2009

Ondansetron relieves withdrawal symptoms without side effects, early study shows

WEDNESDAY, Feb. 18 (HealthDay News) -- A drug currently used to treat nausea can prevent symptoms of withdrawal from illegal and prescription opioid drugs such as heroin, morphine and codeine, a new study shows.

The Stanford University scientists behind the research added it can do so without some of the serious side effects caused by existing treatments for addiction to these drugs.

Initial tests in mice showed that the drug ondansetron (Zofran) blocks certain 5-HT3 receptors involved in withdrawal symptoms, the researchers said. They then tested it in eight healthy, non-opioid-dependent volunteers who were given two doses of morphine, once without ondansetron and one with it, and found ondansetron reduced withdrawal symptoms in humans.

The study appears in the Feb. 17 online issue of the Journal of Pharmacogenetics and Genomics.

"Opioid abuse is rising at a faster rate than any other type of illicit drug use, yet only about a quarter of those dependent on opioids seek treatment. One barrier to treatment is that when you abruptly stop taking the drugs, there is a constellation of symptoms associated with withdrawal," lead author Dr. Larry F. Chu, an assistant professor of anesthesia, said in a Stanford news release.

Those symptoms include agitation, insomnia, diarrhea, nausea and vomiting. Current methods of treating withdrawal symptoms aren't completely effective or cause severe side effects, requiring constant patient supervision.

"What we need is a magic bullet, something that treats the symptoms of withdrawal, does not lead to addiction and can be taken at home," Chu added.

The Stanford team plans to continue testing the effectiveness of ondansetron in treating opioid addiction and to conduct a clinical study to determine the effectiveness of an ondansetron-like drug in treating opioid addiction.

However, the researchers noted that ondansetron alone can't solve the problems caused by opioid addiction, which is a long-term, complex process that involves both physical and psychological factors.

"This is not a cure for addiction. It's naive to think that any one receptor is a panacea for treatment. Treating the withdrawal component is only one way of alleviating the suffering. With luck and determination, we can identify additional targets and put together a comprehensive treatment program," principal investigator Dr. J. David Clark, a professor of anesthesia, said in the news release.

More information

The National Institutes of Health has more about opiate withdrawal.



-- Robert Preidt



SOURCE: Stanford University, news release, Feb. 17, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Oncologists Rank Aloxis Marketing Message Most Influential in the Chemotherapy-Induced Nausea and Vomiting Drug Market
2. SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Chemotherapy Patients, Now Available
3. FDA Approves Aloxi(R) (Palonosetron HCL) Injection for Prevention of Postoperative Nausea and Vomiting
4. Explaining chemotherapy-associated nausea
5. Mayo Clinic study finds FDA warning against antinausea drug droperidol unnecessary
6. Acupuncture does not reduce radiotherapy-induced nausea, but patients believe it does
7. No Link Between Anti-Nausea Drug, Heart Trouble
8. HotHead Technologies Heat Sensor Shows Exciting Potential by Kennesaw State University Researchers
9. Partnership for Prevention: CDC Report Shows Compelling Need for FDA Regulation of Tobacco
10. New CDC Study Shows Tobacco Marketing Influences Kids to Smoke, Underscores Need for FDA Regulation of Tobacco Products
11. Caregivers not receiving the help they need, study shows
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Nausea Drug Shows Promise Against Opioid Addiction
(Date:6/27/2016)... ... June 27, 2016 , ... ... announced today its affiliation with Tennessee Counseling Association. This new relationship ... of the Tennessee Counseling Association, adding exclusive benefits and promotional offers. , "TCA ...
(Date:6/26/2016)... ... , ... Quality metrics are proliferating in cancer care, and are derived from ... of the beholder, according to experts who offered insights and commentary in the current ... For the full issue, click here . , For the American Society of ...
(Date:6/26/2016)... Charlotte, NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind ... able to be personalized through a fitness app. The fitness app plans to fix the ... solutions currently only offer a one size fits all type program , They ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 ... brings up a new, often overlooked aspect of head lice: the parasite’s ability to live ... not a common occurrence, but a necessary one in the event that lice have simply ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... , June 26, 2016 One of Australia,s ... announced the formation of a new biotechnology company, Noxopharm Limited [ABN ... in an IPO and to list on the ASX. ... NOX66, ready to enter a Phase 1 clinical study later this ... to address one of the biggest problems facing cancer patients - ...
(Date:6/26/2016)... DUBLIN , June 27, 2016 Jazz ... the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... proposed acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... 11:59 p.m. (Eastern Daylight Time). As previously ... entered into a definitive merger agreement under which Jazz ...
(Date:6/26/2016)... 27, 2016  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ... whatever measures required to build a strong and stable ... currently listed on the OTC Markets-pink current trading platform. ... CEO, "We are seeing an anomaly in market trading ... only by the Company, but shareholders and market players ...
Breaking Medicine Technology: